Lansoprazole Patent Expiration
Lansoprazole was first introduced by Takeda Pharmaceuticals Usa Inc
Lansoprazole Patents
Given below is the list of patents protecting Lansoprazole, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Lansoprazole | US11077055 | Orally disintegrating compositions | Apr 21, 2036 | Dexcel |
| Lansoprazole | US11986554 | Orally disintegrating compositions | Apr 21, 2036 | Dexcel |
| Prevacid Iv |
US7396841 (Pediatric) | Injections |
Feb 17, 2022
(Expired) | Takeda Pharms Na |
| Prevacid Iv | US7396841 | Injections |
Aug 17, 2021
(Expired) | Takeda Pharms Na |
| Prevacid |
US6328994 (Pediatric) | Orally disintegrable tablets |
Nov 17, 2019
(Expired) | Takeda Pharms Usa |
| Prevacid |
US7431942 (Pediatric) | Orally disintegrable tablets |
Nov 17, 2019
(Expired) | Takeda Pharms Usa |
| Prevacid |
US7875292 (Pediatric) | Orally disintegrable tablets |
Nov 17, 2019
(Expired) | Takeda Pharms Usa |
| Prevacid |
US9901546 (Pediatric) | Orally disintegrable tablets |
Nov 17, 2019
(Expired) | Takeda Pharms Usa |
| Prevacid | US6328994 | Orally disintegrable tablets |
May 17, 2019
(Expired) | Takeda Pharms Usa |
| Prevacid | US7431942 | Orally disintegrable tablets |
May 17, 2019
(Expired) | Takeda Pharms Usa |
| Prevacid | US7875292 | Orally disintegrable tablets |
May 17, 2019
(Expired) | Takeda Pharms Usa |
| Prevacid | US9901546 | Orally disintegrable tablets |
May 17, 2019
(Expired) | Takeda Pharms Usa |
| Prevacid |
US7399485 (Pediatric) | Rapidly Disintegrable solid preparation |
Nov 26, 2018
(Expired) | Takeda Pharms Usa |
| Prevacid | US7399485 | Rapidly Disintegrable solid preparation |
May 26, 2018
(Expired) | Takeda Pharms Usa |
| Prevacid |
US5464632 (Pediatric) | Rapidly disintegratable multiparticular tablet |
May 07, 2013
(Expired) | Takeda Pharms Usa |
| Prevacid | US5464632 | Rapidly disintegratable multiparticular tablet |
Nov 07, 2012
(Expired) | Takeda Pharms Usa |
A patent's expiry date may change depending upon legal activities going on that patent. Critical
activities like
abandoning of a patent, term extension of a patent or amendment of its claims can increase or
decrease the life of a
patent hence affecting its expiry date and in turn affecting the generic launch date of that
drug. Tracking these
ongoing activities on a patent application helps to keep an eye on the latest developments in
the patent process of
the drug which can give an idea of how early a drug's generic could be available. The next
section provides a list
of recent legal activities on Lansoprazole's patents.
Latest Legal Activities on Lansoprazole's Patents
Given below is the list recent legal activities going on the following patents of Lansoprazole.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 4th Year, Large Entity | 28 Jan, 2025 | US11077055 |
| Electronic Review | 07 Jun, 2024 | US11986554 |
| Patent Issue Date Used in PTA Calculation | 21 May, 2024 | US11986554 |
| Mail Patent eGrant Notification | 21 May, 2024 | US11986554 |
| Patent eGrant Notification | 21 May, 2024 | US11986554 |
| Recordation of Patent Grant Mailed | 21 May, 2024 | US11986554 |
| Recordation of Patent eGrant | 21 May, 2024 | US11986554 |
| Email Notification | 21 May, 2024 | US11986554 |
| Email Notification | 02 May, 2024 | US11986554 |
| Issue Notification Mailed | 01 May, 2024 | US11986554 |
Lansoprazole's Family Patents
Explore Our Curated Drug Screens
Clinical Trials
Recent Clinical Trials on Lansoprazole:
Sometimes companies keep conducting clinical trials even after the drug's approval to discover new formulations, methods of use, or new treatment indications, so they could file for additional patents or receive regulatory exclusivity extensions, such as pediatric exclusivity, potentially delaying generic competition. Based on these recent clinical trials, generic companies need to consider the potential for new intellectual property or regulatory hurdles. These strategic moves by the drug owner might delay generic substitution or lead to additional sales of the brand drug, even after patent expiry.
| Title | Lead Sponsor | Collaborators | Status | Phases |
|---|---|---|---|---|
 | ||||
| A Study Comparing the Effect and Safety of Linaprazan Glurate to Lansoprazole in Participants With Erosive Esophagitis (EE) Due to Gastroesophageal Reflux Disease (GERD) | Cinclus Pharma Holding AB | NA |
ACTIVE NOT RECRUITING
(Aug 1, 2026)
| PHASE3 |
| Phase 3 to Evaluate the Efficacy and Safety of DWP14012 in Patients With Gastric Ulcer | Daewoong Pharmaceutical Co. LTD. | NA |
NOT YET RECRUITING
(Jul 1, 2026)
| PHASE3 |
| A Study Comparing the Effect and Safety of Linaprazan Glurate to Lansoprazole in Maintenance of Healing in Participants With Healed Erosive Esophagitis (EE) Due to Gastroesophageal Reflux Disease (GERD) | Cinclus Pharma Holding AB | NA |
WITHDRAWN
(May 1, 2026)
| PHASE3 |